These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22627904)

  • 1. Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective.
    Pishko AM; Smith KJ; Ragni MV
    Thromb Haemost; 2012 Aug; 108(2):303-10. PubMed ID: 22627904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.
    Smith KJ; Monsef BS; Ragni MV
    Thromb Haemost; 2008 Sep; 100(3):447-52. PubMed ID: 18766261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.
    Johnston JA; Brill-Edwards P; Ginsberg JS; Pauker SG; Eckman MH
    Am J Med; 2005 May; 118(5):503-14. PubMed ID: 15866253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
    Seaman CD; Smith KJ; Ragni MV
    Thromb Res; 2013; 132(6):647-51. PubMed ID: 24139508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.
    Carrier M; Le Gal G; Cho R; Tierney S; Rodger M; Lee AY
    J Thromb Haemost; 2009 May; 7(5):760-5. PubMed ID: 19245418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.
    Coleman CI; Limone BL; Bookhart BK; Mody SH; Nutescu EA
    Thromb Res; 2014 May; 133(5):743-9. PubMed ID: 24582461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis.
    Nguyen GC; Bernstein CN
    Am J Gastroenterol; 2013 Sep; 108(9):1486-95. PubMed ID: 23857476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients.
    Spangler EL; Dillavou ED; Smith KJ
    J Vasc Surg; 2010 Dec; 52(6):1537-45.e1-2. PubMed ID: 20843631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery.
    Bradley CT; Brasel KJ; Miller JJ; Pappas SG
    Ann Surg Oncol; 2010 Jan; 17(1):31-9. PubMed ID: 19707830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
    Deitelzweig SB; Becker R; Lin J; Benner J
    Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.
    You JH
    Pharmacogenet Genomics; 2014 Jan; 24(1):6-14. PubMed ID: 24168919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty.
    Schousboe JT; Brown GA
    J Bone Joint Surg Am; 2013 Jul; 95(14):1256-64. PubMed ID: 23864173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
    de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
    Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation.
    Sud S; Mittmann N; Cook DJ; Geerts W; Chan B; Dodek P; Gould MK; Guyatt G; Arabi Y; Fowler RA; ;
    Am J Respir Crit Care Med; 2011 Dec; 184(11):1289-98. PubMed ID: 21868500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.